PURPOSE: The primary aim in the study is to determine if quetiapine treatment is associated with greater reduction in alcohol use than placebo in outpatients with bipolar disorder and alcohol dependence. We will also examine if quetiapine treatment is associated with greater reduction in alcohol craving than placebo in outpatients with bipolar disorder and alcohol dependence and if quetiapine treatment is associated with greater improvement in depressive symptoms than placebo in outpatients with bipolar disorder and alcohol dependence.

PROJECT SUMMARY: The study is open to men and women age 18-65 years old, English or Spanish speaking. Participants must meet the diagnosis of bipolar I or II disorder, depressed or mixed phase on the SCID and confirmed by interview with PI or co-I. Participants must also meet a current diagnosis of alcohol dependence with alcohol use (by self-report) of at least 15 drinks in the 7 days prior to baseline. Participants will also be taking a mood stabilizer such as lithium, divalproex/valproic acid, oxcarbazepine, or lamotrigine at a stable dose for > 14 days.

BACKGROUND:  The negative impact of substance abuse on bipolar disorder is well documented. Studies report decreased quality of life, increased hospitalization, and lower rates of recovery during hospitalization in bipolar patients with substance abuse. In addition, aggression and violence were significantly greater in bipolar disorder patients with a history of substance abuse. Substance abuse is also associated with medication non-compliance in patients with bipolar disorder.

Frequently Asked Questions
Q: How old I must be to participate in this study?
A: This study includes persons between the ages 18 -65 years.

Q: How long can I expect to be in this study?
A: A person is expected to participate in the study for 12 weeks, with weekly visits.

Q: Will I be paid if I take part in this study?
A: Yes, you will be compensated for each assessment. Food coupons and bus passes will also be provided for each visit.